Results for Blood Disorders

Dr. Chou focuses on regenerative blood cellular therapy, the mechanisms of normal human hematopoietic development, and the pathophysiology of pediatric hematologic diseases.

Dr. Rivella is an expert in the pathophysiology of erythroid and iron disorders and in the generation of lentiviral vectors for the cure of hemoglobinopathies. He also investigates additional disorders such as anemia of inflammation and hemochromatosis.

Dr. Eugene Khandros is a physician-scientist with a clinical and research focus on disorders of red blood cells and hemoglobin production.

Dr. Chang is a clinical investigator focusing on cardiovascular assessment and outcomes of pediatric-onset systemic lupus erythematosus (pSLE). Her research assesses the utility of various screening modalities, including echocardiography, ambulatory blood pressure monitoring, and tonometry, for the early detection of cardiovascular disease. Her research goals are to develop screening protocols and targeted interventions to prevent pSLE-related cardiovascular morbidity and mortality.

Dr. Douglas has extensive laboratory experience investigating the cellular immunology of HIV/AIDS, primary immune deficiency diseases, and cellular immunopathologies. In addition, he has had significant involvement in studies related to immunological interactions.

Dr. Shah's research is centered on understanding obesity and its related complications. Her current work includes clinical and translational studies exploring pathophysiology and modulation of obesity-related adipose tissue and systemic inflammation using human cell lines and clinical trials. She is also involved in clinical studies of outcomes and risk factors of polycystic ovarian syndrome and type 2 diabetes in teens.

Dr. Denburg addresses fundamental limitations in understanding of skeletal morbidity in patients with chronic kidney disease, glomerular disease, and urinary stone disease, and develops resources to conduct observational research and trials to optimize health outcomes in these high risk populations.

Dr. Mostoufi-Moab's clinical and research program is focused on endocrine late effects after childhood cancer therapy. She has unique dual training in pediatric endocrinology and oncology with a master's degree in clinical epidemiology. The goal of her research program is to pursue a mechanistic understanding of metabolic and endocrine disorders that occur due to cancer therapy.

Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.

Dr. French came to CHOP in 2008 to establish the Human Pluripotent Stem Cell Core in the Center for Cellular and Molecular Therapeutics. She is an internationally recognized researcher involved in multi-investigator teams that utilize pluripotent stem cells for modeling human disease to study mechanism, development, and establish new therapeutic modalities.